

11 December 2025

Upcoming release of escrowed securities

Enlitic, Inc. (ASX: ENL) (“the Company”) advises, in accordance with ASX Listing Rule 3.10A, that the following restricted securities (as defined in the Replacement Prospectus dated 22 November 2023 and lodged with the ASX on 18 December 2023) subject to mandatory escrow restrictions will be released from escrow at 4:15pm on Friday 19 December 2025:

- 7,558,404 Shares of common stock (equivalent to 7,558,404 CDIs);
- 76,551 Warrants (equivalent to 76,551 CDIs upon exercise); and
- 9,750,816 Options (equivalent to 9,750,816 CDIs upon exercise).

– ENDS –

This announcement was authorised for release by the Company Secretary.

Enquiries

Enlitic Investor Relations

Australia:
invest_au@enlitic.com

About Enlitic

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com.

For personal use only

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.

For personal use only